27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Mizuho Securities assumes coverage of Axsome Therapeutics Inc (NASDAQ:AXSM), with a Buy rating and a price target of $76, representing a 25% upside from the last close is 55% above the initial price target of $49.
- The analyst is conservative on revenues relative to consensus over the near- and mid-term. It is also below consensus on the cost/expense side, finding merit in Axsome's disciplined spending approach.
- Related: Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says.
- Mizuho sees modest novelty in AXSM's candidates, and the markets it addresses feature meaningful branded and generic competition.
- The analyst also notes that a potentially significant opportunity exists given large markets (e.g., major depressive disorder and migraine) and limited efficacy seen with current standards of care.
- Price Action: AXSM shares are up 0.22% at $60.92 on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!